Black Diamond Therapeutics, Inc. (BDTX): Cash & Equivalents
$20.99M
As of 2025-12-31
$19.19M
As of 2026-06-30
-15.1%
3-year compound annual growth
-9.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.99M | -42.4% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $36.44M | -35.2% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $56.22M | +63.8% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $34.31M | -47.8% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $65.80M | +90.1% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $34.60M | -77.6% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $154.67M | +199.4% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $51.66M | n/a | 2020-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $743.29M | +25.1% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $104.13M | -54.2% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
Compare BDTX, VIR, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗